Shengquan Group(SH:605589)2021-10-25 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥2,277,585,614.49, a decrease of 6.14% compared to the same period last year[2]. - The net profit attributable to shareholders for Q3 2021 was ¥153,863,279.58, down 38.86% year-on-year[2]. - The basic earnings per share for Q3 2021 was ¥0.22, reflecting a decline of 39.64% compared to the previous year[4]. - The company reported a net cash flow from operating activities of -¥1,902,297,196.07 for the year-to-date period[4]. - The company attributed the decline in profits to the high profits from mask sales in the same period last year due to the pandemic[7]. - The total comprehensive income attributable to the parent company's owners for Q3 2021 was CNY 525,384,236.55, a decrease from CNY 666,094,246.92 in Q3 2020, representing a decline of approximately 21.1%[18]. - The company's basic and diluted earnings per share for Q3 2021 were both CNY 0.75, down from CNY 0.95 in Q3 2020, representing a decline of approximately 21.1%[18]. - Net profit for the third quarter was ¥539,944,035.49, down from ¥672,050,450.62, representing a decline of approximately 19.6%[17]. Assets and Liabilities - The total assets at the end of Q3 2021 amounted to ¥13,106,568,025.56, representing an increase of 20.11% from the end of the previous year[4]. - The total current assets as of September 30, 2021, amounted to 6,781.60 million RMB, compared to 5,559.24 million RMB in the previous year[13]. - The company reported a significant increase in long-term fixed assets, reaching 2,944.10 million RMB compared to 2,094.83 million RMB in the previous year[13]. - The total liabilities amounted to ¥5,175,742,472.74, slightly down from ¥5,179,393,841.66, indicating a decrease of about 0.1%[14]. - The company's total liabilities increased, with a notable rise in borrowings, reflecting ongoing financing needs and potential strategic investments[22]. - Total liabilities reached approximately ¥5.18 billion, with current liabilities at ¥2.72 billion and non-current liabilities at ¥2.45 billion[24]. Equity - The equity attributable to shareholders increased by 38.82% year-on-year, reaching ¥7,778,128,011.41[4]. - The equity attributable to shareholders increased to ¥7,778,128,011.41 from ¥5,603,168,773.78, showing a growth of approximately 38.8%[15]. - Shareholders' equity totaled approximately ¥5.73 billion, with equity attributable to the parent company at ¥5.60 billion[25]. Revenue Segments - The company's revenue increased by 0.95% year-on-year despite a significant decline in the health protection products segment[11]. - Sales revenue from health protection products was 232.55 million RMB, with a gross profit of 59.08 million RMB during the reporting period[11]. - Excluding health protection products, other main business segments achieved sales revenue of 6,029.29 million RMB, a year-on-year growth of 43.22%[11]. - The gross profit from other main business segments was 1,485.39 million RMB, reflecting a year-on-year increase of 33.73%[11]. Cash Flow - The net cash flow from operating activities for the first nine months of 2021 was -CNY 1,902,297,196.07, compared to -CNY 93,072,992.54 in the same period of 2020, indicating a significant deterioration in cash flow[20]. - The net cash flow from investing activities for the first nine months of 2021 was -CNY 920,598,125.47, compared to -CNY 404,467,165.52 in the same period of 2020, indicating increased cash outflows for investments[21]. - The net cash flow from financing activities for the first nine months of 2021 was CNY 2,214,139,700.40, a significant increase from CNY 440,405,896.69 in the same period of 2020, showing improved financing activities[21]. - The total cash and cash equivalents at the end of Q3 2021 were CNY 943,821,327.71, compared to CNY 671,472,501.07 at the end of Q3 2020, indicating an increase of approximately 40.5%[21]. Research and Development - Research and development expenses increased to ¥290,108,745.80 from ¥235,451,235.39, marking a rise of about 23.2%[17]. - The company is focusing on high-performance resins, composite materials, and biomass refining to enhance its industrial ecosystem[11]. Initial Public Offering - The company completed its initial public offering in August 2021, contributing to the increase in equity[7].